Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

gn up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements
This press release contains "forward-looking" statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development and our ability to submit the above-referenced tosedostat data to the FDA in the coming weeks. Such statements are subject to risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the Company's securities. Specifically, the risks and uncertainties that could affect our ability to address FDA requests or the development of tosedostat more generally include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with tosedostat in particular including, without limitation, the potential failure of tosedostat to prove safe and effective as determined by the FDA and/or the European Medicines Agency; determinations by regulatory, patent, and administrative governmental authorities; competitive factors; technological developments; costs of developing and producing tosedostat; the risk that the FDA may expand its information request or initiate a complete clinical hold or take other actions; and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission, including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. The Company can give no assurances that any results or events projected or contemplated by its forward-looking statements will in fact occur and the Company cautions you not to place undue reliance on these statements. The Company undertakes no duty to update these forward-looking statements to reflect any future events, d
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Cryoport, Inc. ... "Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, announced today that ... common stock and warrants (the "Units") under a registered ...
(Date:7/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/sxwk89/3d_metrology ) ... Market by Product (CMM, ODS, and VMM), Application (Automotive, ... (North America, Europe, APAC, RoW) - Global Forecast to ... The 3D metrology market was valued at $1,456.7 ... a rate of 7.11% during the forecast period. ...
(Date:7/29/2015)... Inc., a privately-held regenerative medicine company with the first stem cell-derived ... today announced the opening of a second site in its Phase ... olerability, and E fficacy of VC-01™ Combination P roduct ... the first in Canada , will be at ... Alberta.  The lead Edmonton ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Global 3D Metrology Market 2015-2020: Products (CMM, ODS, and VMM) & Applications (Automotive, Aerospace, Energy & Power, Medical and Electronics) 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
... -- Encorium Group, Inc. (Nasdaq: ENCO ... conducting studies in over 30 countries for many of ... that it has appointed Sari Laitinen to its Board ... age 43, will replace Jyrki Mattila who has rendered ...
... Pa., Nov. 13 ReSearch Pharmaceutical Services, Inc. ("RPS" ... development outsourcing solutions to the bio-pharmaceutical industry, is pleased ... nine months ended September 30, 2009. These statements ... and nine months ended September 30, 2008. , In ...
Cached Medicine Technology:Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 2Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 3ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 2ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 3ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 4ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 5ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 6ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 7ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 8ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 9ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 10ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 11
(Date:7/29/2015)... ... 2015 , ... Wedding season is in full swing, which means bridal beauty prep is officially ... on the big day. Every bride wants to look and feel beautiful, but a recent ... to a recent study by the American Academy of Facial Plastic and ...
(Date:7/29/2015)... ... 2015 , ... CanAm Enterprises, LLC (“CanAm”) is thrilled to announce that more ... have been granted to investors in four different CanAm EB-5 projects -- the Sony ... Philadelphia, and the Valley Forge Convention Center project in CanAm’s regional center in partnership ...
(Date:7/29/2015)... ... July 29, 2015 , ... July is National UV Awareness Month, and in honor ... shares tips on how to protect skin from the sun, as well as how to ... and is one of the most common skin conditions in America. Many people do not ...
(Date:7/29/2015)... ... , ... A June 10, 2015 article from the News-Press, entitled " It's ... having regular skin cancer screenings from an early age. Skin cancer can strike at ... early, skin cancer is rarely fatal; however, if left alone for too long, the ...
(Date:7/29/2015)... ... July 29, 2015 , ... Employee Fiduciary, LLC announces the launch of ... information, website, types of plans administered, years in business, and credentials of all Employee ... least one plan with Employee Fiduciary. A search can be done by zip code ...
Breaking Medicine News(10 mins):Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Employee Fiduciary Launches Financial Advisor Directory 2
... in Britain has concluded on Tuesday that although organic ... compared to conventional milk//, it did not provide any ... reached following assessment of the evidence on the nutritional ... group of scientists who wrote to the FSA recently ...
... people suffering from severe chronic lung disease associated with ... ,Chronic Bronchitis and Emphysema constitute the condition, Chronic ... by smoking can lead to the development of lung ... West, director of tobacco studies at Cancer Research UK's ...
... Don’t blame yourself, if your taste buds get tickled at ... mere mention! A recent investigation into the reasons// for ... that such tendencies are gene-centric. ,All the same, ... the body balances the requirement of minerals and nutrients, to ...
... there is one with pre-diabetes. Pre-diabetes is the precursor stage ... ,"There is one diabetic person for every 10 Mumbaikars, ... Shashank Joshi. ,The occurrence of diabetes is going to rise ... years. ,"Mumbai is a hub for pre-diabetes," says Joshi. ...
... UK-wide Specialty training programme, aiming to Modernize Medical Careers, ... before the commencement of the program//; Doctors from Scotland ... and whether doctors will be given the option of ... requests in a letter addressed to the Scottish Junior ...
... that pregnant women may be risking their own health as well ... said that in a survey over 7 percent pregnant women admitted ... is one to two units once or twice a week. "There ... because any amount can pass through the placenta to the baby. ...
Cached Medicine News:Health News:80% of lung disease remains ‘undiagnosed’. 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: